ArticleJournal of acquired immune deficiency syndromes (1999)2026
Incidence and Risk Factors for Non-AIDS Comorbidities After COVID-19 in People Living With HIV in Atlanta, Georgia.
Article in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCoronavirus disease 2019 (COVID-19) infection rates disproportionately affect persons with underlying health conditions. People living with HIV (PLWH) acquire COVID at a higher rate than those without HIV and may be at risk for developing incident comorbidities after acute infection. Risk factors for, and incidence of, post-COVID non-AIDS comorbidities (NACM) in PLWH remain unknown.
settingWe assessed incidence of and risk factors for post-COVID NACM among PLWH using data from the Emory Center for AIDS Research Registry between March 1, 2020, and September 30, 2022. We assessed 8 NACM: cardiometabolic disease, cardiovascular disease, chronic kidney disease, diabetes mellitus, hypertension, lung disease, neurologic disease, and psychiatric disease.
methodsIncidence of and risk factors for post-COVID NACM were evaluated using Cox proportional hazards regression models.
resultsAmong 3540 PLWH (median age 51 years, 69% male, 86% Black, median CD4 + T cell count 415 cells/mm 3 , 72% HIV RNA <200 copies/mL), 261 (7%) COVID+. COVID+ participants had a higher baseline NACM burden (38% vs 9% with > 3 NACM), a longer time to developing any NACM (198 vs 96 days), and similar risk of developing any NACM compared with the COVID-group [hazard ratio (95% confidence interval) 0.65 (0.45, 0.93)].
conclusionsPLWH during the COVID pandemic were at risk for incident NACM regardless of COVID infection status. Although limited by small sample size, our findings suggest that the pandemic itself, beyond infection, may have contributed to an increase in post-COVID comorbidities in PLWH, particularly among those with preexisting comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.